Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) is a pioneering diagnostics technology company focused on expanding access to novel molecular diagnostic testing, primarily in the transplanted organ rejection testing category. The company's website is www.imdxinc.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Insight Molecular Diagnostics Inc. does
In the company’s own words
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) is a pioneering diagnostics technology company focused on expanding access to novel molecular diagnostic testing, primarily in the transplanted organ rejection testing category. The company's website is www.imdxinc.com.
The company operates through a decentralized testing model designed to empower customers such as hospitals, transplant centers, and laboratories to run tests in-house rather than relying on centralized send-out testing. This approach positions testing capabilities directly with clinicians including surgeons, nephrologists, and oncologists, as well as researchers and laboratory directors.
iMDx's primary near-term strategic market is organ transplant diagnostics. The company's flagship technology quantifies donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker established as a trusted indicator of transplanted organ rejection. Under the GraftAssure brand, the company offers GraftAssureCore, a laboratory developed test (LDT) currently reimbursed by Medicare and performed at the company's CLIA-certified laboratory in Franklin, Tennessee; GraftAssureIQ, a research use only kit; and GraftAssureDx, an in vitro diagnostic kit currently in development. These assays are performed on digital PCR instruments manufactured by Bio-Rad Laboratories, with which iMDx maintains a global strategic partnership for kitted product development and commercialization.
The company's secondary strategic market focuses on oncology diagnostics, including DetermaIO and DetermaCNI assays, though commercialization of these products is not planned within the next twelve months. iMDx also provides assay development and clinical testing services for life sciences and biotechnology companies through its Laboratory Services operations.
The company maintains research and development laboratories in Nashville, Tennessee and Göttingen, Germany, with the Germany facility serving as the center of excellence for blood-based monitoring programs. iMDx's intellectual property portfolio was substantially expanded through acquisitions of Insight Genetics, Inc. in 2020 and Chronix Biomedical, Inc. in 2021, providing exclusive rights to additional patents, trademarks, and trade secrets in cell-free DNA detection and quantification technologies.
Company details
- Sector
- Materials
- Industry
- Chemicals
- Headquarters
- NASHVILLE, TN
- Fiscal year end
- December
- CIK
- 1642380
- SIC
- 2835
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Insight Molecular Diagnostics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Insight Molecular Diagnostics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Insight Molecular Diagnostics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Insight Molecular Diagnostics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Insight Molecular Diagnostics Inc.'s last four quarterly filings that the numbers alone won't show?”